Georgia Marquez-Grap
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Georgia Marquez-Grap has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
Andrea Leung
6 shared publications- Wilson Liao
Department of Dermatology, University of California, San Francisco, San Francisco, California, USA
5 shared publications Allison Kranyak
Department of Dermatology, University of California, San Francisco, San Francisco, USA
4 shared publications- Allison Kranyak
Department of Dermatology, University of California San Francisco, San Francisco, USA
4 shared publications Isabel Muraguri
3 shared publicationsPetronilla Biwott
3 shared publications
Latest Publications
- Open Access
- 26 May 2026
- Published by Elsevier in JAAD Case Reports
- Vol. 74, 70-74
Modified Goeckerman therapy for chronic skin diseases in a resource-limited setting: A case series from Kenya
- 26 May 2026
- Published by Elsevier in JAAD Case Reports
- Vol. 74, 70-74
Open AccessModified Goeckerman therapy for chronic skin diseases in a resource-limited setting: A case series from Kenya
- Open Access
- 9 March 2026
- Published by SAGE Publications in Journal of Psoriasis and Psoriatic Arthritis®
Determinants of Quality of Life and Mental Health in Kenyan Psoriasis Patients: A Cross-Sectional Analysis from the Kenyan Psoriasis Registry
Purpose: Psoriasis is a chronic immune-mediated disease with global prevalence of 2-3% that is associated with significantly reduced quality of life (QoL) and worsened mental health. Despite this, there is a lack of research in African psoriasis populations, with no modern epidemiological studies conducted in Kenya to examine these factors. This study aims to identify demographic and clinical features associated with dermatology-related QoL and mental health among psoriasis patients enrolled in the newly established Kenyan Psoriasis Registry (KPR), based at Moi Teaching and Referral Hospital in Eldoret, Kenya. Patients and Methods: In a cross-sectional analysis of 97 adult psoriasis patients enrolled in the KPR, we evaluated associations of demographic and disease characteristics with independent outcomes of dermatology-associated QoL (Dermatology Life Quality Index, DLQI), anxiety (Generalized Anxiety Disorder 7-item, GAD-7), and depression (Patient Health Questionnaire 9-item, PHQ-9). Univariate and multivariate linear regression models were used to identify associations, with P < 0.05 considered statistically significant. Results: In univariate analyses, age, female gender, marital status, certain subethnicities, high-impact body sites, itch and pain, sleep disturbance, and disease severity were factors associated with worse QoL, anxiety, and depression scores. In multivariate analyses, younger age, Itch Numeric Rating Scale, and Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance T-score remained significantly associated with worse DLQI. Both PROMIS Sleep Disturbance and separated marital status were associated with worse GAD-7 and PHQ-9. Conclusion: Kenyan psoriasis patients experience significant QoL and mental health burden, with younger age, itch, sleep disturbance, and separated marital status associated with worse outcomes.
- 9 March 2026
- Published by SAGE Publications in Journal of Psoriasis and Psoriatic Arthritis®
Open AccessDeterminants of Quality of Life and Mental Health in Kenyan Psoriasis Patients: A Cross-Sectional Analysis from the Kenyan Psoriasis Registry
Purpose: Psoriasis is a chronic immune-mediated disease with global prevalence of 2-3% that is associated with significantly reduced quality of life (QoL) and worsened mental health. Despite this, there is a lack of research in African psoriasis populations, with no modern epidemiological studies conducted in Kenya to examine these factors. This study aims to identify demographic and clinical features associated with dermatology-related QoL and mental health among psoriasis patients enrolled in the newly established Kenyan Psoriasis Registry (KPR), based at Moi Teaching and Referral Hospital in Eldoret, Kenya. Patients and Methods: In a cross-sectional analysis of 97 adult psoriasis patients enrolled in the KPR, we evaluated associations of demographic and disease characteristics with independent outcomes of dermatology-associated QoL (Dermatology Life Quality Index, DLQI), anxiety (Generalized Anxiety Disorder 7-item, GAD-7), and depression (Patient Health Questionnaire 9-item, PHQ-9). Univariate and multivariate linear regression models were used to identify associations, with P < 0.05 considered statistically significant. Results: In univariate analyses, age, female gender, marital status, certain subethnicities, high-impact body sites, itch and pain, sleep disturbance, and disease severity were factors associated with worse QoL, anxiety, and depression scores. In multivariate analyses, younger age, Itch Numeric Rating Scale, and Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance T-score remained significantly associated with worse DLQI. Both PROMIS Sleep Disturbance and separated marital status were associated with worse GAD-7 and PHQ-9. Conclusion: Kenyan psoriasis patients experience significant QoL and mental health burden, with younger age, itch, sleep disturbance, and separated marital status associated with worse outcomes.
- Open Access
- 20 December 2025
- Published by Springer Nature in Dermatology and Therapy
- Vol. 16 (2) , 1011-1023
Establishment of the Kenyan Psoriasis Registry: A Case–Control Cohort
Introduction Psoriasis is a chronic inflammatory skin disease with a global prevalence of 1–5%, however its clinical and demographic profile in Kenya remains underexplored. This article describes the establishment of the Kenyan Psoriasis Registry at Moi Teaching and Referral Hospital in Eldoret, Kenya. Methods 214 subjects were enrolled between October 2024 and August 2025 at Moi Teaching and Referral Hospital. Both healthy controls and patients with psoriasis completed enrollment surveys and physical exams, and donated saliva samples. Results The initial cohort of 214 subjects (108 patients with psoriasis, 106 healthy controls) provides valuable insights into the demographics, clinical profiles, quality of life, and mental health characteristics of patients with psoriasis in Kenya. The mean age of psoriasis onset was 30.4 years, and mean age of diagnosis by a medical provider was 38.9 years old. 13.9% of patients with psoriasis reported a positive family history of psoriasis, and 9.3% of patients with psoriasis reported a diagnosis of psoriatic arthritis. The mean psoriasis area and severity index was 9.9 and mean Investigator Global assessment score was 3.0. Examination of treatment patterns revealed that moisturizers, prescription topical medications, and methotrexate were commonly tried while only 9.3% of individuals had ever received a biologic therapy. Patients with psoriasis reported significantly worse sleep disturbance, quality of life, and mental health compared to healthy controls. Conclusion This data highlights the unique characteristics of patients with psoriasis in Kenya. The Kenyan Psoriasis Registry continues to enroll patients and conduct yearly follow-ups, aiming to deepen the understanding of psoriasis in this population. These findings underscore the need for targeted research and advocacy to improve psoriasis care in Kenya.
- 20 December 2025
- Published by Springer Nature in Dermatology and Therapy
- Vol. 16 (2) , 1011-1023
Open AccessEstablishment of the Kenyan Psoriasis Registry: A Case–Control Cohort
Introduction Psoriasis is a chronic inflammatory skin disease with a global prevalence of 1–5%, however its clinical and demographic profile in Kenya remains underexplored. This article describes the establishment of the Kenyan Psoriasis Registry at Moi Teaching and Referral Hospital in Eldoret, Kenya. Methods 214 subjects were enrolled between October 2024 and August 2025 at Moi Teaching and Referral Hospital. Both healthy controls and patients with psoriasis completed enrollment surveys and physical exams, and donated saliva samples. Results The initial cohort of 214 subjects (108 patients with psoriasis, 106 healthy controls) provides valuable insights into the demographics, clinical profiles, quality of life, and mental health characteristics of patients with psoriasis in Kenya. The mean age of psoriasis onset was 30.4 years, and mean age of diagnosis by a medical provider was 38.9 years old. 13.9% of patients with psoriasis reported a positive family history of psoriasis, and 9.3% of patients with psoriasis reported a diagnosis of psoriatic arthritis. The mean psoriasis area and severity index was 9.9 and mean Investigator Global assessment score was 3.0. Examination of treatment patterns revealed that moisturizers, prescription topical medications, and methotrexate were commonly tried while only 9.3% of individuals had ever received a biologic therapy. Patients with psoriasis reported significantly worse sleep disturbance, quality of life, and mental health compared to healthy controls. Conclusion This data highlights the unique characteristics of patients with psoriasis in Kenya. The Kenyan Psoriasis Registry continues to enroll patients and conduct yearly follow-ups, aiming to deepen the understanding of psoriasis in this population. These findings underscore the need for targeted research and advocacy to improve psoriasis care in Kenya.
- Open Access
- 29 September 2025
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 36 (1) , 2555983
Monitoring atopic dermatitis using mobile-app based photography and surveys
Remote clinical research has potential to increase study diversity, reduce costs for researchers and participants, and increase efficiency of studies. This study evaluates the reliability and feasibility of using SkinTracker, a mobile application, for remote AD severity assessment through mobile-app based photography and surveys. This single-center observational study enrolled 28 participants (18 with AD and 10 healthy controls) in an eight-week hybrid clinical study. Participants completed bi-weekly tasks and submitted standardized skin photographs via the SkinTracker app, and clinic-based skin exams and digital single-lens reflex (SLR) photos were obtained at baseline and week 8. Eczema Area Severity Index and Investigator Global Assessment scores were assigned to the photographs by a grader. Intraclass correlation coefficients were used to evaluate agreement between app-based, in-person, and SLR assessments for the 18 participants with AD. App-based AD assessment scores had excellent agreement with in-person scores, indicating the reliability of SkinTracker to assess disease activity remotely. Furthermore, all participants had high compliance and satisfaction with app-based activities, indicating that using SkinTracker for remote clinical research is achievable and even preferred by participants. Overall, these findings show that SkinTracker is both reliable and feasible for monitoring atopic dermatitis disease activity remotely.
- 29 September 2025
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 36 (1) , 2555983
Open AccessMonitoring atopic dermatitis using mobile-app based photography and surveys
Remote clinical research has potential to increase study diversity, reduce costs for researchers and participants, and increase efficiency of studies. This study evaluates the reliability and feasibility of using SkinTracker, a mobile application, for remote AD severity assessment through mobile-app based photography and surveys. This single-center observational study enrolled 28 participants (18 with AD and 10 healthy controls) in an eight-week hybrid clinical study. Participants completed bi-weekly tasks and submitted standardized skin photographs via the SkinTracker app, and clinic-based skin exams and digital single-lens reflex (SLR) photos were obtained at baseline and week 8. Eczema Area Severity Index and Investigator Global Assessment scores were assigned to the photographs by a grader. Intraclass correlation coefficients were used to evaluate agreement between app-based, in-person, and SLR assessments for the 18 participants with AD. App-based AD assessment scores had excellent agreement with in-person scores, indicating the reliability of SkinTracker to assess disease activity remotely. Furthermore, all participants had high compliance and satisfaction with app-based activities, indicating that using SkinTracker for remote clinical research is achievable and even preferred by participants. Overall, these findings show that SkinTracker is both reliable and feasible for monitoring atopic dermatitis disease activity remotely.
- 5 August 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 52 (Suppl 3) , 55-58
MHC-I-opathy: A Unified Concept for the Etiology of Several Major Histocompatibility Complex–Associated Conditions Including Psoriasis and Psoriatic Arthritis
At the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2024 annual meeting, Drs. Dennis McGonagle and Wilson Liao discussed “MHC-I-opathies,” a class of immune-mediated diseases genetically associated with major histocompatibility complex class I (MHC-I) and class I peptide processing. MHC-I-opathies demonstrate epistatic interactions, genetic associations, and immunopathology that are distinct from classic B cell and autoantibody-driven autoimmune diseases. Investigations into the pathomechanisms of MHC-I-opathies have revealed a blend of tissue-specific innate immunity and CD8 T cell responses. Several functional pathomechanisms by which MHC-I molecules increase psoriasis (PsO) susceptibility were presented by McGonagle and Liao, and there were multiple associations within the HLA-C locus. Antigen presentation to T cells, HLA regulation of natural killer cells and CD8 T cells through killer immunoglobulin-like receptors, and HLA regulation of dendritic cells through leukocyte immunoglobulin-like receptors were discussed. Interestingly, MHC-I associations are not only linked to excessive inflammation in MHC-I-opathies but also to the spontaneous suppression of infection (eg, HIV-1 elite controllers). This striking prominence of MHC-I in PsO and antiviral immunity provides insight into why autoimmune alleles are maintained in the human genome and how protective antiviral pathways may be linked to aberrant activation of MHC-I-opathies. Outside of spinal inflammation in HLA-B27–positive axial psoriatic arthritis (PsA), the basis for MHC-I genetics in PsA remains less clear and is at least partly linked to greater PsA heterogeneity. Understanding the contribution of MHC-I in PsO and PsA may have important implications for therapy development.
- 5 August 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 52 (Suppl 3) , 55-58
MHC-I-opathy: A Unified Concept for the Etiology of Several Major Histocompatibility Complex–Associated Conditions Including Psoriasis and Psoriatic Arthritis
At the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2024 annual meeting, Drs. Dennis McGonagle and Wilson Liao discussed “MHC-I-opathies,” a class of immune-mediated diseases genetically associated with major histocompatibility complex class I (MHC-I) and class I peptide processing. MHC-I-opathies demonstrate epistatic interactions, genetic associations, and immunopathology that are distinct from classic B cell and autoantibody-driven autoimmune diseases. Investigations into the pathomechanisms of MHC-I-opathies have revealed a blend of tissue-specific innate immunity and CD8 T cell responses. Several functional pathomechanisms by which MHC-I molecules increase psoriasis (PsO) susceptibility were presented by McGonagle and Liao, and there were multiple associations within the HLA-C locus. Antigen presentation to T cells, HLA regulation of natural killer cells and CD8 T cells through killer immunoglobulin-like receptors, and HLA regulation of dendritic cells through leukocyte immunoglobulin-like receptors were discussed. Interestingly, MHC-I associations are not only linked to excessive inflammation in MHC-I-opathies but also to the spontaneous suppression of infection (eg, HIV-1 elite controllers). This striking prominence of MHC-I in PsO and antiviral immunity provides insight into why autoimmune alleles are maintained in the human genome and how protective antiviral pathways may be linked to aberrant activation of MHC-I-opathies. Outside of spinal inflammation in HLA-B27–positive axial psoriatic arthritis (PsA), the basis for MHC-I genetics in PsA remains less clear and is at least partly linked to greater PsA heterogeneity. Understanding the contribution of MHC-I in PsO and PsA may have important implications for therapy development.
- Open Access
- 15 July 2025
- Published by SAGE Publications in Journal of Psoriasis and Psoriatic Arthritis®
- Vol. 11 (1) , 34-38
Understanding Patient Priorities for Psoriatic Disease Research
Background: There have been significant advances in psoriatic disease research in recent years, leading to better understanding of genes involved and increased treatment options. Purpose: To guide current research priorities for psoriatic disease, we held an interactive session on this topic consisting of a presentation and small group discussion with National Psoriasis Foundation (NPF) patient-volunteers, their family members, and NPF staff at the NPF 2025 IMPACT Volunteer Leadership Summit. Research design: We presented a list of 10 psoriatic research topics and asked attendees to rate the priority of each topic on a 9-point scale. The session also included breakout groups where attendees discussed research areas most important to them. Study Sample: National Psoriasis Foundation (NPF) patient-volunteers, their family members, and NPF staff at the NPF 2025 IMPACT Volunteer Leadership Summit. Data collection and/or Analysis: Attendees completed an online REDCap survey which was then analyzed by the study team. Results: “Improving treatment for psoriatic disease and achieving remission” was the research topic that received the highest overall rating. We also learned of research topics of high patient interest not included on our original list of 10 topics, including research exploring the relationship between psoriatic disease and hormones, infertility, and menopause. Increased research on pediatric psoriatic disease and research initiatives focused on increased patient and provider education were topics of importance to attendees as well. Conclusion: Overall, these findings may help guide future patient-centered research agendas in psoriatic disease.
- 15 July 2025
- Published by SAGE Publications in Journal of Psoriasis and Psoriatic Arthritis®
- Vol. 11 (1) , 34-38
Open AccessUnderstanding Patient Priorities for Psoriatic Disease Research
Background: There have been significant advances in psoriatic disease research in recent years, leading to better understanding of genes involved and increased treatment options. Purpose: To guide current research priorities for psoriatic disease, we held an interactive session on this topic consisting of a presentation and small group discussion with National Psoriasis Foundation (NPF) patient-volunteers, their family members, and NPF staff at the NPF 2025 IMPACT Volunteer Leadership Summit. Research design: We presented a list of 10 psoriatic research topics and asked attendees to rate the priority of each topic on a 9-point scale. The session also included breakout groups where attendees discussed research areas most important to them. Study Sample: National Psoriasis Foundation (NPF) patient-volunteers, their family members, and NPF staff at the NPF 2025 IMPACT Volunteer Leadership Summit. Data collection and/or Analysis: Attendees completed an online REDCap survey which was then analyzed by the study team. Results: “Improving treatment for psoriatic disease and achieving remission” was the research topic that received the highest overall rating. We also learned of research topics of high patient interest not included on our original list of 10 topics, including research exploring the relationship between psoriatic disease and hormones, infertility, and menopause. Increased research on pediatric psoriatic disease and research initiatives focused on increased patient and provider education were topics of importance to attendees as well. Conclusion: Overall, these findings may help guide future patient-centered research agendas in psoriatic disease.
- 3 June 2025
- Published by Elsevier in Rheumatic Disease Clinics of North America
- Vol. 51 (3) , 417-431
Molecular Biomarkers and Clinical Predictors of Psoriatic Arthritis
- 3 June 2025
- Published by Elsevier in Rheumatic Disease Clinics of North America
- Vol. 51 (3) , 417-431
Molecular Biomarkers and Clinical Predictors of Psoriatic Arthritis
- Open Access
- 3 May 2025
- Published by Springer Nature in Dermatology and Therapy
- Vol. 15 (7) , 1599-1606
The Impact of Step Therapy on Individuals with Psoriatic Disease in the USA: Patient and Provider Perspectives
The management of psoriatic disease has been revolutionized by biologic medications in recent years. Despite their efficacy and safety, patients are often required by insurance plans in the USA or national formulary guidelines in other countries to try and fail other treatments first, which is a strategy called step therapy. Originally designed to contain costs of specialty drugs, step therapy has a number of negative impacts on patients and providers, both personally and clinically. This article is coauthored by a patient with psoriasis and psoriatic arthritis who navigated step therapy. She describes her early experiences with psoriasis and achieving disease control with biologic medication, only to later be diagnosed with psoriatic arthritis and need to revise this treatment plan. She then explains how insurance denials and step therapy impact her life physically, emotionally, socially, and medically. This case is then discussed from the perspective of a dermatologist specializing in inflammatory skin disease. We highlight the psychosocial burden of psoriatic disease, as well as the burden of step therapy and its impacts on patients, providers, and the entire medical system.
- 3 May 2025
- Published by Springer Nature in Dermatology and Therapy
- Vol. 15 (7) , 1599-1606
Open AccessThe Impact of Step Therapy on Individuals with Psoriatic Disease in the USA: Patient and Provider Perspectives
The management of psoriatic disease has been revolutionized by biologic medications in recent years. Despite their efficacy and safety, patients are often required by insurance plans in the USA or national formulary guidelines in other countries to try and fail other treatments first, which is a strategy called step therapy. Originally designed to contain costs of specialty drugs, step therapy has a number of negative impacts on patients and providers, both personally and clinically. This article is coauthored by a patient with psoriasis and psoriatic arthritis who navigated step therapy. She describes her early experiences with psoriasis and achieving disease control with biologic medication, only to later be diagnosed with psoriatic arthritis and need to revise this treatment plan. She then explains how insurance denials and step therapy impact her life physically, emotionally, socially, and medically. This case is then discussed from the perspective of a dermatologist specializing in inflammatory skin disease. We highlight the psychosocial burden of psoriatic disease, as well as the burden of step therapy and its impacts on patients, providers, and the entire medical system.
- Open Access
- 23 February 2025
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 36 (1) , 2466635
Can pimozide kill parasites? Surprisingly, the most honest answer is ‘yes’
Purpose: One of the most well-known medications for treating delusional infestation (DI) is pimozide. Many patients may be reluctant to initiate treatment unless a medication has anti-pathogenic properties, as they feel otherwise it does not address their concerns regarding infestation. In this article, we explore the evidence that pimozide has a range of antipathogenic effects and how this fact can aid in patient care. Materials and methods: A scoping literature review was performed using The National Library of Medicine (PubMed). The search terms used were pimozide AND anti-microbial OR anti-bacterial OR anti-infective. All relevant articles were reviewed up to September 2024. Results: Our findings show that pimozide has antibacterial and antiparasitic effects through several unique mechanisms. Additionally, several older first-generation antipsychotics also have demonstrated anti-pathogenic properties. While the studies identified are entirely in vitro, the potential antipathogenic effects of pimozide may be pivotal to patients with DI as they make the critical decision to accept or reject treatment. Conclusion: With adequate disclaimers that pimozide's therapeutic efficacy may not have to do with its anti-pathogen profile, the evidence that pimozide has anti-pathogenic properties may enable dermatology providers to strengthen their therapeutic approach and alliance with patients with DI and make life-changing therapy more acceptable to the patient.
- 23 February 2025
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 36 (1) , 2466635
Open AccessCan pimozide kill parasites? Surprisingly, the most honest answer is ‘yes’
Purpose: One of the most well-known medications for treating delusional infestation (DI) is pimozide. Many patients may be reluctant to initiate treatment unless a medication has anti-pathogenic properties, as they feel otherwise it does not address their concerns regarding infestation. In this article, we explore the evidence that pimozide has a range of antipathogenic effects and how this fact can aid in patient care. Materials and methods: A scoping literature review was performed using The National Library of Medicine (PubMed). The search terms used were pimozide AND anti-microbial OR anti-bacterial OR anti-infective. All relevant articles were reviewed up to September 2024. Results: Our findings show that pimozide has antibacterial and antiparasitic effects through several unique mechanisms. Additionally, several older first-generation antipsychotics also have demonstrated anti-pathogenic properties. While the studies identified are entirely in vitro, the potential antipathogenic effects of pimozide may be pivotal to patients with DI as they make the critical decision to accept or reject treatment. Conclusion: With adequate disclaimers that pimozide's therapeutic efficacy may not have to do with its anti-pathogen profile, the evidence that pimozide has anti-pathogenic properties may enable dermatology providers to strengthen their therapeutic approach and alliance with patients with DI and make life-changing therapy more acceptable to the patient.
- 23 June 2020
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 60 (1) , 108-112
Patient adherence with a smartphone app for patient-reported outcomes in rheumatoid arthritis
Objectives: Electronic patient-reported outcomes (ePROs) transmitted digitally allow patients to communicate with their clinicians and track the activity of chronic diseases, such as RA. Several ePRO smartphone apps have been developed in rheumatology, yet few data have been reported regarding patient adherence. We developed a PRO app for RA and assessed adherence over 6 months. Methods: We developed an app to deliver daily assessments to participants (RA App v.1.0). The app was tested as part of a randomized controlled trial examining potential clinical benefits. The current analyses focus on the adherence to the ePRO app for patients randomized to receive the app. We recruited RA patients from an academic rheumatology practice in the USA. Patients randomized to receive the app received daily notifications regarding ePROs. We examined adherence to the PRO questionnaires over the 6-month study and examined factors related to adherence. Results: Seventy-eight patients received the app and have data included in these analyses: 63 (80.7%) were female, mean age was 55.2 years, 71% had attended college or beyond, and the mean Clinical Disease Activity Index at baseline was 9.7 (low disease activity). Median adherence to the daily questions was 79% (interquartile range 48–90%). Significant predictors of increased adherence were age ≥65 (P = 0.03) and low baseline Clinical Disease Activity Index (P = 0.02). Conclusion: We developed and tested an ePRO app for RA over a 6-month study. Adherence to the app was strong. There was correlation between older age and better disease control and increased adherence. Trial registration: ClinicalTrials.gov, https://clinicaltrials.gov/, NCT02822521.
- 23 June 2020
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 60 (1) , 108-112
Patient adherence with a smartphone app for patient-reported outcomes in rheumatoid arthritis
Objectives: Electronic patient-reported outcomes (ePROs) transmitted digitally allow patients to communicate with their clinicians and track the activity of chronic diseases, such as RA. Several ePRO smartphone apps have been developed in rheumatology, yet few data have been reported regarding patient adherence. We developed a PRO app for RA and assessed adherence over 6 months. Methods: We developed an app to deliver daily assessments to participants (RA App v.1.0). The app was tested as part of a randomized controlled trial examining potential clinical benefits. The current analyses focus on the adherence to the ePRO app for patients randomized to receive the app. We recruited RA patients from an academic rheumatology practice in the USA. Patients randomized to receive the app received daily notifications regarding ePROs. We examined adherence to the PRO questionnaires over the 6-month study and examined factors related to adherence. Results: Seventy-eight patients received the app and have data included in these analyses: 63 (80.7%) were female, mean age was 55.2 years, 71% had attended college or beyond, and the mean Clinical Disease Activity Index at baseline was 9.7 (low disease activity). Median adherence to the daily questions was 79% (interquartile range 48–90%). Significant predictors of increased adherence were age ≥65 (P = 0.03) and low baseline Clinical Disease Activity Index (P = 0.02). Conclusion: We developed and tested an ePRO app for RA over a 6-month study. Adherence to the app was strong. There was correlation between older age and better disease control and increased adherence. Trial registration: ClinicalTrials.gov, https://clinicaltrials.gov/, NCT02822521.